Phyllis Gotlib Sells 4,959 Shares of American Well (NYSE:AMWL) Stock

Key Points

• Phyllis Gotlib sold 4,959 shares of American Well stock for approximately $30,299, reducing her ownership by 3.75% to 127,151 shares.
• American Well's stock is currently trading around $6.34, with a market cap of $102.39 million, and has a 50-day moving average price of $6.97.
• Several analysts have rated American Well as a "Hold," with a consensus price target of $9.17, despite a recent adjustment in price objective from Wells Fargo from $15.00 to $12.00.

American Well Corporation (NYSE:AMWL - Get Free Report) insider Phyllis Gotlib sold 4,959 shares of American Well stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $6.11, for a total transaction of $30,299.49. Following the transaction, the insider owned 127,151 shares in the company, valued at approximately $776,892.61. The trade was a 3.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Phyllis Gotlib also recently made the following trade(s):

• On Tuesday, September 2nd, Phyllis Gotlib sold 4,781 shares of American Well stock. The shares were sold at an average price of $6.78, for a total value of $32,415.18.

American Well Trading Up 3.6%

NYSE:AMWL traded up $0.22 on Friday, hitting $6.34. 126,496 shares of the company's stock traded hands, compared to its average volume of 60,342. The firm has a 50-day moving average price of $6.97 and a 200-day moving average price of $7.29. American Well Corporation has a 1 year low of $5.98 and a 1 year high of $12.95. The company has a market cap of $102.39 million, a PE ratio of -0.79 and a beta of 1.26.

American Well (NYSE:AMWL - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($1.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.84) by $0.60. American Well had a negative return on equity of 41.99% and a negative net margin of 46.15%.The firm had revenue of $70.90 million during the quarter, compared to analysts' expectations of $63.87 million. American Well has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts forecast that American Well Corporation will post -9.34 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Weiss Ratings restated a "sell (e+)" rating on shares of American Well in a report on Saturday, September 27th. Wells Fargo & Company reduced their price objective on shares of American Well from $15.00 to $12.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. One research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $9.17.

Hedge Funds Weigh In On American Well

Large investors have recently added to or reduced their stakes in the company. Headlands Technologies LLC bought a new stake in shares of American Well during the second quarter valued at approximately $39,000. Sapient Capital LLC bought a new stake in American Well in the 1st quarter valued at $79,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of American Well in the 2nd quarter valued at $89,000. Engineers Gate Manager LP bought a new stake in American Well in the second quarter valued at about $101,000. Finally, JPMorgan Chase & Co. raised its position in American Well by 16.5% in the second quarter. JPMorgan Chase & Co. now owns 14,720 shares of the company's stock worth $131,000 after purchasing an additional 2,081 shares in the last quarter. Institutional investors and hedge funds own 56.05% of the company's stock.

About American Well

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.